Beam Therapeutics (BEAM) Net Cash Flow (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Net Cash Flow data on file, last reported at -$6.6 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$6.6 million, down 102.72% year-over-year; the trailing twelve-month figure through Mar 2026 was -$239.5 million (down 199.72% YoY), and the FY2025 annual result was $11.5 million, up 107.45% from the prior year.
• Net Cash Flow retreated to -$6.6 million in Q1 2026 per BEAM's latest filing, from $27.0 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $266.9 million in Q4 2023 and troughed at -$263.2 million in Q1 2022.
• A 5-year average of -$16.3 million and a median of -$14.1 million in 2025 frame the typical range for Net Cash Flow.
• On a YoY basis, Net Cash Flow climbed as much as 262.6% in 2025 and fell as far as 5422.76% in 2025.
• A 5-year view of Net Cash Flow shows it stood at $76.3 million in 2022, then jumped by 249.97% to $266.9 million in 2023, then plunged by 80.01% to $53.4 million in 2024, then plunged by 49.39% to $27.0 million in 2025, then plunged by 124.57% to -$6.6 million in 2026.
• Business Quant data shows BEAM's Net Cash Flow at -$6.6 million in Q1 2026, $27.0 million in Q4 2025, and -$14.1 million in Q3 2025.